"Our company worked very closely with Nuvisan in 2024. Nuvisan conducted several of our clinical pharma studies from different programs, and all studies were completed on time and with high quality."

Head of Clin. Pharm (HV) & Trial Supplies Management 

Merck KGaA, Germany 

“As a drug hunter and builder of seed-stage biotech companies, I depend on CROs to deliver early proof-of-concept for novel therapeutic strategies. In my experience, there is no better partner than Nuvisan to design and execute derisking studies and to implement early stage drug discovery workflows. Nuvisan’s team of thoughtful and creative scientists have helped me get several academic drug discovery projects on a solid technical footing. For example, the core discovery technology that we use at Tilikum Tx was transferred and optimized by Nuvisan scientists, turning a specialized and difficult to operate academic technique into a powerful drug discovery tool. In-house expertise from early stage discovery through late stage preclinical development makes Nuvisan the logical home base for Tilikum’s small molecule program.”

Lev Osherovich, Ph.D.

CSO and Founding Director
Tilikum Therapeutics Inc. 

“Nuvisan has supported us with clinical trial supply services for years. With their expertise and excellent collaboration, we were able to achieve our goals. Thank you and we are looking forward to potential future projects.” 

Dr. Petra Igličar 

Global Head of Pharmaceutical Development 
Immunic Therapeutics, Germany

“Our collaboration with Nuvisan has been a great success. The seamless integration of their phase I unit with next-door bioanalytical capabilities has provided unparalleled efficiency and precision for our project. Their ability to combine preclinical activities with expert support in metabolism profiling has been a game-changer for our development program. Their expertise and commitment are highly valued, making them a trusted partner." 

Pierre Saint-Mezard, Ph.D. 

Chief Scientific Officer 
Vaderis Therapeutics, Switzerland

"My company used Nuvisan for a high-throughput screening campaign which had proven difficult in establishing. Nuvisan scientists were professional and experienced, and the screening library was clearly higher quality than commercially available ones. The final compounds we licensed were excellent leads with drug-like properties. As a result of the success of this project, we then initiated two additional HTS campaigns with Nuvisan."

Vice President

US Pharmaceutical

“We have been working successfully with Nuvisan on preclinical studies for some time. We particularly appreciate the highly competent advice on the design of new projects as well as the reliable and professional execution.”

Priv. Doz. Dr. Frank Westermann

Group Leader
Hopp Kindertumorzentrum (KiTZ) and Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany

“We have been very impressed with Nuvisan’s overall chemistry consulting capabilities, in terms of both our overall medicinal chemistry design strategy as well as their rapid execution on project teams.  Nuvisan’s scientists are currently collaborating with us on multiple high priority, highly competitive, hit-to-lead and lead optimization programs. Our collaborators at Nuvisan have always been rapidly responsive, fully versed on week-to-week data, and innovative with their scientific solutions to program obstacles. Currently, one of those projects is now poised to start first-in-human studies while another has made excellent progress and is now in late-stage lead optimization. The Nuvisan team’s breadth and depth of experience have been critical to the success of these projects, and we truly view them as an extension of our internal chemistry team here at Nimbus. It’s been a pleasure to work with them and we are looking forward to continuing our collaboration with them on current and future projects!”
 

Scott Edmondson, Ph.D.

Senior Vice President of Chemistry
Nimbus Therapeutics, USA 

"We highly recommend Nuvisan to anyone seeking a reliable partner for in vivo efficacy studies. We appreciate their excellent experimental capacities and study management, as well as open and constructive scientific discussions that allow us to collaborate efficiently on multiple projects. Their dedication, flexibility, and quality make them an invaluable support in our preclinical drug development."

Dr. Janet Peper-Gabriel

Head of Discovery and Preclinical 
Plectonic Biotech, Germany

"We highly value our collaboration with Nuvisan for their competent, approachable and likeable team. They consistently demonstrate proactive thinking, constructive solutions and a seamless, easy-going approach to every project. Nuvisan is a trustworthy partner at eye level."

Senior Director Preclinical Development 

Mid-sized Pharma 
Vienna, Austria 

“We are very happy to have your support always at the highest professional level. […] 
Your comprehensive analysis of the available data, coupled with your insightful recommendations, have been extremely valuable. I deeply appreciate the effort and attention to detail you put into preparing for our discussion. As always, your expertise has helped us better understand compound-related concerns, and we received good advice on what to do next.” 

Head of DMPK – Associate Director 

Head of Discovery and Preclinical 
Molecure SA, Poland 

“Nuvisan’s clinical team performed our first-in-human SAD/MAD studies. Their scientific input and timely execution were cornerstones for the success of our clinical trials. The quality and structured work from the entire Nuvisan team has prompted us to engage Nuvisan’s bioanalytical and biometrics teams to support our entire clinical program for several years."  

Clinical Operations Team Leader 

Bioversys, Switzerland

“We are pleased to share our positive experience with Nuvisan as a Science CRO that has been instrumental in our non-GMP Affilin® protein production for preclinical in vivo studies. The team of experienced scientists and researchers possesses a comprehensive understanding of microbial processes and protein purification technologies, which has greatly contributed to the success of our projects. To date, we have successfully completed three projects in 2024 and 2025, with two additional projects currently ongoing in 2025. The quick turnaround in proposal generation and the open, fair pricing policy made the collaboration seamless and efficient. Regular communication regarding project status has been a standout feature of our partnership. The team has maintained transparency and has been proactive in addressing any anomalies immediately, providing us with their own solutions, which fostered a strong sense of trust and collaboration.
The swift execution of projects and the high quality of the results delivered have consistently exceeded our expectations. Overall, the Nuvisan team impressed with their professionalism, dedication, and exceptional results in the field of protein production. They have proven to be a valuable partner in our research endeavors.”

Dr. Madlen Zwarg

Project Manager
Navigo Proteins GmbH, Germany